Market Place
Sourcing Support
Chiesi To Present Respiratory Leadership Data At ATS 2024
16 May 2024 //
GLOBENEWSWIRE
Chiesi USA CEO Appointed to ASHP Foundation Board of Directors
20 Jul 2023 //
GLOBENEWSWIRE
Chiesi USA Partners with Smith Anderson to Host 1L Excellence
12 Jun 2023 //
GLOBENEWSWIRE
2022 for Chiesi: The Group international growth continues
11 Apr 2023 //
GLOBENEWSWIRE
Chiesi`s international growth continues
05 Apr 2023 //
PR NEWSWIRE
Chiesi Announces Approval of FERRIPROX MR Deferiprone Extended-Release Tablets
01 Apr 2023 //
PR NEWSWIRE
Chiesi donates more than $830,000 to local communities and nonprofits in 2022
28 Mar 2023 //
GLOBENEWSWIRE
Chiesi USA Sponsors ASHP Advantage Initiative to Support Pharmacy Technician
02 Dec 2022 //
GLOBENEWSWIRE
Chiesi Announces Publication of Health Economics Analysis of Rescue Surfactant
29 Nov 2022 //
GLOBENEWSWIRE
Chiesi USA Chosen as One of Fortune’s 25 Best Small & Medium Workplaces
17 Oct 2022 //
GLOBENEWSWIRE
Chiesi USA Partners with Durham Bulls to Donate $15,000
03 Oct 2022 //
GLOBENEWSWIRE
Chiesi USA Reports Progress in ASHP Foundation’s Pharmacy Leadership Scholars
06 Sep 2022 //
GLOBENEWSWIRE
Chiesi USA Announces 1st Analysis from the CAMEO Registry Assessing KENGREAL Use
01 Jun 2022 //
GLOBENEWSWIRE
Chiesi USA certified as a Great Place to Work® in 2021
24 Feb 2022 //
GLOBENEWSWIRE
Chiesi USA Publishes Post Hoc Analysis on Ischemic Events & KENGREAL`s role
25 Jan 2022 //
GLOBENEWSWIRE
Chiesi Global Rare Diseases Announces Approval of FERRIPROX in Brazil for SCD
13 Sep 2021 //
PRNEWSWIRE
Chiesi USA Announces Publication of Cost-Consequence Analysis of KENGREAL
10 Aug 2021 //
BIOSPACE
Chiesi USA Announces Publication of Cost-Consequence Analysis of KENGREAL
10 Aug 2021 //
BIOSPACE
Icario and ConnectureDRX Partner to Deliver a Seamless Enrollment Experience
23 Jun 2021 //
GLOBENEWSWIRE
Chiesi Pharma`s Curosurf (Poractant Alfa) Receives Approval In US
19 May 2021 //
FDA
Moderna, ChiesiGroup Collaborate on Discovery & Development of mRNA Therapeutics
22 Sep 2020 //
PHARMATECH
Moderna lands $100M upfront in deals with Vertex, Chiesi
18 Sep 2020 //
FIERCE BIOTECH
Moderna & Chiesi Group Establish Collaboration for PAH
17 Sep 2020 //
BIOSPACE
Protalix &Chiesi Global Rare Diseases Announce USFDA (BLA) for Pegunigalsidase
11 Aug 2020 //
PRNEWSWIRE
Chiesi Group Bayer announce co-promotion agreement for respiratory Clenil
17 Jul 2020 //
PRESS RELEASE
Protalix and Chiesi Global Rare Diseases Announce Submission of Biologics
27 May 2020 //
PRNEWSWIRE
Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone)
21 May 2020 //
YAHOO
Chiesi creates Boston rare disease unit ahead of Fabry launch
08 Feb 2020 //
FIERCE BIOTECH
Chiesi Group & Apotex Inc. finalize agreement for acquisition of Ferriprox®
13 Jan 2020 //
GLOBENEWSWIRE
Chiesi to invest 350 million euros in eco-friendly asthma options
04 Dec 2019 //
THE PHARMA LETTER
First patient dosed with Chiesi’s Holoclar
01 Nov 2019 //
PHARMATIMES
Chiesi announces two successful sets of asthma data
17 Oct 2019 //
PHARMATIMES
Protalix BioTherapeutics & Chiesi Group Complete PhIII Trial of (PRX?102)
24 Sep 2019 //
BUSINESSWIRE
Enforcement Report - Week of June 19, 2019
19 Jun 2019 //
FDA
Protalix, Chiesi fire up accelerated approval pitch for Fabry disease treatment
07 Jun 2019 //
ENDPTS
Inhibrx files for $75M IPO
04 Jun 2019 //
FIERCE BIOTECH
Inhibrx inks agreement with Chiesi Group to develop & commercialize INBRX-101
30 May 2019 //
PHARMABIZ
Inhibrx Announces Option Agreement for Devp & Commercialization of INBRX-101
30 May 2019 //
PR NEWSWIRE
Chiesi pays $105m to license ophthalmological drug
28 May 2019 //
IN-PHA RMATECHNOLOGIST
Santhera, Chiesi Group Enter Raxone License Agreement
24 May 2019 //
CONTRACT PHARMA
NICE rejects Chiesi’s Lamzede
24 May 2018 //
PHARMA TIMES
NC Biotech Center awards $2.65M in grants, loans in two latest quarters
04 May 2018 //
WRALTECHWIRE
Chiesi Farmaceutici`s Lamzede (Velmanase alfa) Receives Approval In Europe
13 Apr 2018 //
EMA
EU green light for Chiesi’s Lamzede
05 Apr 2018 //
PHARMA TIMES
Chiesi`s ultra-rare genetic disorder therapy wins European backing
01 Feb 2018 //
PMLIVE
NICE backs Europe`s first stem cell therapy
25 Aug 2017 //
PMLIVE
Johnson & Johnson in breach of U.K. rules over Nicorette marketing
16 Aug 2017 //
MMM ONLINE
Chiesi Group`s Trimbow wins European licence
03 Aug 2017 //
PMLIVE
EU nod for Chiesi’s COPD therapy
26 Jul 2017 //
PHARMA TIMES
Horizon Completes Sale of EU Mkt Rights for PROCYSBI®&QUINSAIR™ in Europe Chiesi
23 Jun 2017 //
PRESS RELEASE
Veloxis signs agreement with Italy’s Chiesi
08 Jun 2017 //
BIOSPECTRUM
Veloxis Announces Agreement with Chiesi Farmaceutici S.p.A.
06 Jun 2017 //
GLOBENEWSWIRE
Horizon Pharma plc Announces Agreement to Sell European Marketing Rights to PROCYSBI
23 May 2017 //
NASDAQ
Chiesi buys Atopix for clinical-stage asthma pipeline
21 Nov 2016 //
FIERCE BIOTECH
Chiesi`s Holoclar wins UK Prix Galien orphan drug award
24 Sep 2016 //
PMLIVE
